About Discovery Genomics
Discovery Genomics is a Healthcare company based in Minneapolis (United States) founded in 2000, and was acquired by Immusoft in March 2016. Gene therapies for blood diseases. Discovery Genomics has raised $4 million across 3 funding rounds from investors including Immusoft, Bio-Techne and HHS. Discovery Genomics offers products and services including Quote Comparison Service. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Discovery Genomics, a functional genomics company created to discover gene functions, conduct drug target validations, and design therapeutic agents based on genomics information. The company holds exclusive licenses from the University of Minnesota to develop technologies related to knock-downs in Zebrafish using a proprietary Morphant(TM) technology and to the use of the Sleeping Beauty Transposon(TM). Both technologies may be used for functional genomics and the discovery of drug targets. The transposon may have applications in gene therapy. Morphant(TM) knock-downs are used to suppress and thereby study the functions of particular genes.
- Headquarters Minneapolis, United States
- Stage Acquired
- SectorsHealthcare
- Website discoverygenomics.net
- Acquired by Immusoft (Mar 2016)
Products & Services of Discovery Genomics
Discovery Genomics offers a comprehensive portfolio of products and services, including Quote Comparison Service.
Online tool for comparing Medicare plans and getting quotes
Funding Insights of Discovery Genomics
Discovery Genomics has successfully raised a total of $4M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.77 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4M
- Total Rounds 3
- Last Round Grant — $1.77M
- First Round $4M
(Aug 2001)
- Investors Count 2
All 3 funding rounds of Discovery Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2011 | $1.77M | Grant | – | – | |
| Mar 2010 | $270,673 | Grant | – | – | |
| Aug 2001 | $4M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Discovery Genomics
Discovery Genomics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Immusoft, Bio-Techne and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of biotech reagents, instruments and clinical diagnostic products | 1981 | bio-techne.com | Minneapolis, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
B cells are programmed as biofactories for therapeutic protein delivery. | 2009 | immusoft.com | Seattle, United States |
Investor details for Discovery Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Discovery Genomics
4 dated milestones of Discovery Genomics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Discovery Genomics is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Grant, of $1.8M.
- Exit Acquired by Immusoft.
Competitors of Discovery Genomics
Discovery Genomics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Discovery Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Discovery Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Discovery Genomics
Discovery Genomics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
Discovery Genomics is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Discovery Genomics is a funded company, having raised a total of $4M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Aug 2001.
Discovery Genomics, a functional genomics company created to discover gene functions, conduct drug target validations, and design therapeutic agents based on genomics information. The company holds exclusive licenses from the University of Minnesota to develop technologies related to knock-downs in Zebrafish using a proprietary Morphant(TM) technology and to the use of the Sleeping Beauty Transposon(TM). Both technologies may be used for functional genomics and the discovery of drug targets. The transposon may have applications in gene therapy. Morphant(TM) knock-downs are used to suppress and thereby study the functions of particular genes.
Discovery Genomics's top competitors include BridgeBio, Forge Biologics and Insitro.
Discovery Genomics offers Quote Comparison Service.
Discovery Genomics has 3 investors. Key investors include Immusoft, Bio-Techne, and HHS.
Yes. Discovery Genomics was acquired by Immusoft in March 2016.